MX2009012705A - Combinacion de inhibidores de cinasa de control y poli(adp-ribosa)polimerasa-1 para el tratamiento de canceres. - Google Patents
Combinacion de inhibidores de cinasa de control y poli(adp-ribosa)polimerasa-1 para el tratamiento de canceres.Info
- Publication number
- MX2009012705A MX2009012705A MX2009012705A MX2009012705A MX2009012705A MX 2009012705 A MX2009012705 A MX 2009012705A MX 2009012705 A MX2009012705 A MX 2009012705A MX 2009012705 A MX2009012705 A MX 2009012705A MX 2009012705 A MX2009012705 A MX 2009012705A
- Authority
- MX
- Mexico
- Prior art keywords
- chk
- combination
- cancers
- treatment
- parp inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94020307P | 2007-05-25 | 2007-05-25 | |
| PCT/GB2008/050372 WO2008146035A1 (en) | 2007-05-25 | 2008-05-23 | Combination of chk and parp inhibitors for the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012705A true MX2009012705A (es) | 2009-12-08 |
Family
ID=39672970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012705A MX2009012705A (es) | 2007-05-25 | 2008-05-23 | Combinacion de inhibidores de cinasa de control y poli(adp-ribosa)polimerasa-1 para el tratamiento de canceres. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100249112A1 (enExample) |
| EP (1) | EP2167086A1 (enExample) |
| JP (1) | JP2010527981A (enExample) |
| KR (1) | KR20100020981A (enExample) |
| CN (1) | CN101743003A (enExample) |
| AU (1) | AU2008256562A1 (enExample) |
| BR (1) | BRPI0811059A2 (enExample) |
| CA (1) | CA2687786A1 (enExample) |
| MX (1) | MX2009012705A (enExample) |
| RU (1) | RU2009147819A (enExample) |
| WO (1) | WO2008146035A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081778A1 (en) * | 2009-01-17 | 2010-07-22 | Universität Zürich | Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer |
| JP2013532683A (ja) | 2010-07-27 | 2013-08-19 | カディラ ヘルスケア リミティド | ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体 |
| US20140044802A1 (en) * | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| DK2938598T3 (en) | 2012-12-31 | 2017-02-13 | Cadila Healthcare Ltd | Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| KR102645511B1 (ko) * | 2017-04-10 | 2024-03-08 | 시에라 온코로지 엘엘씨 | 종양 성장을 저해하는 CHK1(SRA737)/PARPi 조합 방법 |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| CN111936143A (zh) | 2018-04-05 | 2020-11-13 | 诺维嘉研究公司 | 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| CN112375070B (zh) * | 2020-06-29 | 2023-03-28 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| WO2022000946A1 (zh) * | 2020-06-29 | 2022-01-06 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004220321B2 (en) * | 2003-03-12 | 2010-02-25 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
| TWI338000B (en) * | 2003-12-01 | 2011-03-01 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
| WO2005066163A2 (en) * | 2004-01-05 | 2005-07-21 | Astrazeneca Ab | Thiophene derivatives as chk 1 inihibitors |
| WO2006078503A2 (en) * | 2005-01-07 | 2006-07-27 | Arqule, Inc. | Compositions for modulation of parp and methods for screening for same |
| WO2008020180A2 (en) * | 2006-08-17 | 2008-02-21 | Kudos Pharmaceuticals Limited | Methods of increasing the sensitivity of cancer cells to dna damage |
-
2008
- 2008-05-23 RU RU2009147819/15A patent/RU2009147819A/ru not_active Application Discontinuation
- 2008-05-23 JP JP2010508909A patent/JP2010527981A/ja active Pending
- 2008-05-23 CN CN200880024432A patent/CN101743003A/zh active Pending
- 2008-05-23 EP EP08750767A patent/EP2167086A1/en not_active Withdrawn
- 2008-05-23 WO PCT/GB2008/050372 patent/WO2008146035A1/en not_active Ceased
- 2008-05-23 CA CA2687786A patent/CA2687786A1/en not_active Abandoned
- 2008-05-23 AU AU2008256562A patent/AU2008256562A1/en not_active Abandoned
- 2008-05-23 MX MX2009012705A patent/MX2009012705A/es unknown
- 2008-05-23 BR BRPI0811059A patent/BRPI0811059A2/pt not_active IP Right Cessation
- 2008-05-23 US US12/601,328 patent/US20100249112A1/en not_active Abandoned
- 2008-05-23 KR KR1020097026995A patent/KR20100020981A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100020981A (ko) | 2010-02-23 |
| US20100249112A1 (en) | 2010-09-30 |
| CN101743003A (zh) | 2010-06-16 |
| WO2008146035A1 (en) | 2008-12-04 |
| BRPI0811059A2 (pt) | 2017-05-09 |
| RU2009147819A (ru) | 2011-06-27 |
| CA2687786A1 (en) | 2008-12-04 |
| AU2008256562A1 (en) | 2008-12-04 |
| EP2167086A1 (en) | 2010-03-31 |
| JP2010527981A (ja) | 2010-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010003565A (es) | Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina. | |
| TW200716111A (en) | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | |
| WO2007084532A3 (en) | Combination therapy with parp inhibitors | |
| PL1745041T3 (pl) | Inhibitory chinoksalinowe szlaku sygnałowego hedgehog | |
| MY157495A (en) | 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | |
| JO2886B1 (en) | Useful compounds in the inhibition of CHK1 | |
| IL202505A (en) | 2-oxo-3-benzyl-benzoxazole-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, drugs containing them and their uses | |
| PT2073811E (pt) | Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas | |
| TW200801006A (en) | Fused bicyclic mTOR inhibitors | |
| WO2009064444A9 (en) | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
| MX2009003038A (es) | Derivados de quinazolinona 5-sustituidos como agentes antitumorales. | |
| IL180411A0 (en) | Quinazolinone derivatives as parp inhibitors | |
| WO2010077589A3 (en) | Stat3 inhibitors and therapeutic methods using the same | |
| GB0912562D0 (en) | LXR-antagonists for the prevention, reduction or inhibition of scarring | |
| IL219644A0 (en) | Kinase inhibitors and methods of use thereof | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| SI2898887T1 (sl) | Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka | |
| TN2012000205A1 (en) | Method and compositions for treating solid tumors and other malignancies | |
| WO2007140317A3 (en) | Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis | |
| ZA200801332B (en) | Pentacyclic kinase inhibitors | |
| WO2008157563A3 (en) | Deuterium-enriched clopidogrel | |
| UA88655C2 (ru) | S-миртазапин для лечения прилива крови | |
| SI1362590T1 (sl) | Uporaba ciklobradina ali njegovih farmacevtsko sprejemljivih soli za zdravljenje ali preprečevanje | |
| PL1965790T3 (pl) | Metabolity analogów wortmaniny i sposoby ich stosowania | |
| HK1142269A (en) | Combination of chk and parp inhibitors for the treatment of cancers |